Solid Biosciences Inc. (SLDB) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Solid Biosciences Inc. (NASDAQ: SLDB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $6.20 (-2.97% 1D, market cap $664.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SLDB ranks #904 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLDB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FDMT (4D Molecular Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -28.3%, cap $657.4M) and SLBT (SL Science Holding Limited) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $672.9M). Among the 5-stock peer group, SLDB leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).
Per SLDB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001707502), Solid Biosciences Inc. generated $501.8M in revenue (+38.1% YoY), $0 in net income, and -$157.4M in free cash flow against $232.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 31% of 52W Range • RSI-14 at 43 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While SLDB currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.70) and Max Pain ($6.51) forces dealer call-delta covering toward $12.02.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Solid Biosciences Inc. (SLDB) dropped -2.97% to $6.20, trading at 31% of its 52-week range ($3.79 – $11.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
- Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia -- SGT-212 is a first-in-class dual route FA
CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac disease
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SLDB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SLDB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Solid Biosciences Inc. (SLDB) ranks #904 by composite RQD confidence (26/100, grade E) and #402 by equity capitalization ($664.8M). Within this direct 5-issuer industry benchmark cohort, SLDB leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. SLBT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with SLDB at 26/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SLDB
ACTIVE
Solid Biosciences Inc. | E | 26/100 | — | — | -35.0% | -2.97% | $664.8M | Benchmark Subject |
| FDMT 4D Molecular Therapeutics Inc. | D | 44/100 | — | — | -28.3% | -6.89% | $657.4M | /fdmt-vs-sldb → |
| SLBT SL Science Holding Limited | D | 45/100 | — | — | — | +2.56% | $672.9M | /slbt-vs-sldb → |
| CADL Candel Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -3.70% | $637.4M | /cadl-vs-sldb → |
| ATTO Attovia Therapeutics Inc. | D | 44/100 | — | — | — | -0.52% | $693.4M | /atto-vs-sldb → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Solid Biosciences Inc. (SLDB) reported GAAP revenue of $501.8M (+38.1% vs. FY2024 revenue of $363.2M ) , GAAP net income of $0, operating cash flow of -$156.3M, and free cash flow of -$157.4M (-56.4% YoY). On the balance sheet, SLDB closed FY2025 with $232.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $501.8M | $0 | -$156.3M | -$157.4M | $232.5M | — |
| FY2024 (FY) | 2024-12-31 | $363.2M | $0 | -$100.0M | -$100.7M | $188.7M | — |
As of 2026-11-03, Solid Biosciences Inc. (NASDAQ: SLDB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $6.20 (-2.97% 1D, market cap $664.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SLDB ranks #904 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLDB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FDMT (4D Molecular Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -28.3%, cap $657.4M) and SLBT (SL Science Holding Limited) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $672.9M). Among the 5-stock peer group, SLDB leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).
Per SLDB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001707502), Solid Biosciences Inc. generated $501.8M in revenue (+38.1% YoY), $0 in net income, and -$157.4M in free cash flow against $232.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SLDB last traded at $6.20 (-2.97% on volume of 873,136 shares), positioning the stock -19.48% below its 50-day simple moving average ($7.70) and -19.17% below its 200-day simple moving average ($7.67). Across its 52-week range of $3.79 to $11.45, SLDB sits at the 31.5% percentile with a 14-day RSI of 43.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.42 to $6.98).
Per the Roarable RQD rating, SLDB scores 27 and carries a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield -22.98%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). The two weakest pillars, cash generation and insider conviction, indicate that the company is consuming cash without earnings support and that insider activity is not offering a confidence signal. The forensic balance sheet score is the strongest of the five, reflecting a Z-score in the reported range and a moderate Debt/Equity of 0.5, but a Piotroski F-Score of 1/9 signals weak financial health on the rubric's own terms. The rating's message is that downside risk is elevated relative to the reward profile shown in these sources.
Solid Biosciences Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry.
Per the recent news feed, the most prominent items concern European Commission orphan designation for SGT-212 and continued progress in the FALCON trial in Friedreich's Ataxia; this item is flagged RED with a RISK WATCH impact label. Other items, flagged YELLOW with MARKET WIRE labels, include a H.C. Wainwright rating reiteration tied to the EU designation, a Benzinga after-market health care roundup, a Simply Wall St note on cash burn rate, and an ad-hoc-news.de report citing a stock valuation of USD 686.2 million alongside seven presented studies. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Solid Biosciences Inc. (SLDB) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Solid Biosciences Inc. (SLDB) market action, institutional positioning, and fundamental catalysts.
Welcome to the SLDB (Solid Biosciences Inc.) Roar Pit. Current RQD Composite is 27/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on SLDB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Solid Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on SLDB, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $6.39 (52-wk range $3.79 - $11.45), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).